Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ritobegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 7/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ritobegron SCHEMBL5916906 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL1404071 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL4186380 | 1.00 | ADRB3 (0.64) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2949688 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2947591 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2950593 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL2950589 | 0.99 | ADRB3 (0.63) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| Ritobegron SCHEMBL4108225 | 0.92 | ADRB3 (0.58) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| SCHEMBL13653975 | 0.92 | ADRB3 (0.54) | ADRB3ADRB2LMNASLC6A2SLC6A4 | |
| SCHEMBL13653968 | 0.92 | ADRB3 (0.54) | ADRB3ADRB2LMNASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197788-A9 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | claimed |
| EP-1728508-B1 | MEDICINE FOR PREVENTION OR TREATMENT OF FREQUENT URINATION OR URINARY INCONTINENCE | KISSEI PHARMACEUTICAL (JP) | 2009-09-09 | — | — | EP | claimed |
| US-20080306160-A1 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | claimed |
| US-7446128-B2 | Agent for treating interstitial cystitis | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-11-04 | — | — | US | claimed |
| EP-1974725-A1 | SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-10-01 | — | — | EP | claimed |
| EP-1620085-B1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL (JP) | 2008-07-23 | — | — | EP | claimed |
| EP-1938837-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY DECREASE IN LACRIMAL FLUID | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-07-02 | — | — | EP | claimed |
| EP-1572181-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND A SEROTONIN AND/OR NOREPINEPHRINE REUPTAKE INHIBITOR AND THE USE OF SAID COMPOSITION FOR TREATING BLADDER DYSFUNCTION | BOEHRINGER INGELHEIM INT (DE) | 2008-06-25 | — | — | EP | claimed |
| EP-1810673-A1 | THERAPEUTIC AGENT FOR INTERSTITIAL CYSTITIS | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-07-25 | — | — | EP | claimed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | claimed |
| US-20060004105-A1 | Pharmaceutical composition for treating stress incontinence and/or mixed incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | claimed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-02 | — | — | US | claimed |
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | US | claimed |
| WO-2004098586-A1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | WO | claimed |
| US-20040229947-A1 | Method of treating hyperactive bladder using phenoxyacetic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. | 2004-11-18 | — | — | US | claimed |
| EP-1095932-B1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-05-19 | — | — | EP | claimed |
| US-6538152-B1 | Obesity, hyperglycemia, urinary incontinence, intestinal or biliary calculi hypermotility, pollakiuria and depression treatment | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | claimed |
| EP-1095932-A1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885LMNA 2502/4885 |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1686/4885 |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 2025/4885 |
| US-20040229947-A1 | Method of treating hyperactive bladder using phenoxyacetic acid derivatives | BPHL, HTR5A, PNMT | ADRB3 123/4885ADRB2 96/4885LMNA 4385/4885 |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1785/4885 |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1963/4885 |
| US-20060004105-A1 | Pharmaceutical composition for treating stress incontinence and/or mixed incontinence | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.